Abstract
Didanosine (ddI) pharmacokinetics in antepartum and postpartum human immunodeficiency virus (HIV)-infected women and their neonates were studied. HIV-infected pregnant women received an intravenous (iv) ddI infusion (1.6 mg/kg/h) or an oral dose (200 mg bid or 125 mg bid) at 31 weeks antepartum and 6 weeks postpartum. Blood samples were obtained regularly up to 6 or 8 h after drug administration. The same oral dose of ddI (bid) was administered until labor began. Then, ddI was infused iv until delivery. An oral pharmacokinetic study (60 mg/m2) was conducted in infants at day 1 and at week 6 after birth. Plasma concentrations of ddI were measured by radioimmunoassay. After iv ddI administration, only the maternal plasma clearance was found to be significantly increased antepartum (1028 ± 231 mL/min) versus postpartum (707 ± 213 mL/min). No pharmacokinetic parameters after oral administration were significantly affected by pregnancy. The pharmacokinetics of ddI in the neonates were highly variable. We conclude that the oral ddI dose need not be adjusted during pregnancy.
| Original language | English |
|---|---|
| Pages (from-to) | 1536-1541 |
| Number of pages | 6 |
| Journal | Journal of Infectious Diseases |
| Volume | 180 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 9 1999 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Immunology
Cite this
Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates : An AIDS Clinical Trials Group Study. / Wang, Yi; Livingston, Elizabeth; Patil, Shivakumar; McKinney, Ross E.; Bardeguez, Arlene D.; Gandia, Jorge; O'Sullivan, Mary J.; Clax, Pamela; Huang, Sharon; Unadkat, Jashvant D.
In: Journal of Infectious Diseases, Vol. 180, No. 5, 09.11.1999, p. 1536-1541.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates
T2 - An AIDS Clinical Trials Group Study
AU - Wang, Yi
AU - Livingston, Elizabeth
AU - Patil, Shivakumar
AU - McKinney, Ross E.
AU - Bardeguez, Arlene D.
AU - Gandia, Jorge
AU - O'Sullivan, Mary J.
AU - Clax, Pamela
AU - Huang, Sharon
AU - Unadkat, Jashvant D.
PY - 1999/11/9
Y1 - 1999/11/9
N2 - Didanosine (ddI) pharmacokinetics in antepartum and postpartum human immunodeficiency virus (HIV)-infected women and their neonates were studied. HIV-infected pregnant women received an intravenous (iv) ddI infusion (1.6 mg/kg/h) or an oral dose (200 mg bid or 125 mg bid) at 31 weeks antepartum and 6 weeks postpartum. Blood samples were obtained regularly up to 6 or 8 h after drug administration. The same oral dose of ddI (bid) was administered until labor began. Then, ddI was infused iv until delivery. An oral pharmacokinetic study (60 mg/m2) was conducted in infants at day 1 and at week 6 after birth. Plasma concentrations of ddI were measured by radioimmunoassay. After iv ddI administration, only the maternal plasma clearance was found to be significantly increased antepartum (1028 ± 231 mL/min) versus postpartum (707 ± 213 mL/min). No pharmacokinetic parameters after oral administration were significantly affected by pregnancy. The pharmacokinetics of ddI in the neonates were highly variable. We conclude that the oral ddI dose need not be adjusted during pregnancy.
AB - Didanosine (ddI) pharmacokinetics in antepartum and postpartum human immunodeficiency virus (HIV)-infected women and their neonates were studied. HIV-infected pregnant women received an intravenous (iv) ddI infusion (1.6 mg/kg/h) or an oral dose (200 mg bid or 125 mg bid) at 31 weeks antepartum and 6 weeks postpartum. Blood samples were obtained regularly up to 6 or 8 h after drug administration. The same oral dose of ddI (bid) was administered until labor began. Then, ddI was infused iv until delivery. An oral pharmacokinetic study (60 mg/m2) was conducted in infants at day 1 and at week 6 after birth. Plasma concentrations of ddI were measured by radioimmunoassay. After iv ddI administration, only the maternal plasma clearance was found to be significantly increased antepartum (1028 ± 231 mL/min) versus postpartum (707 ± 213 mL/min). No pharmacokinetic parameters after oral administration were significantly affected by pregnancy. The pharmacokinetics of ddI in the neonates were highly variable. We conclude that the oral ddI dose need not be adjusted during pregnancy.
UR - http://www.scopus.com/inward/record.url?scp=0032728821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032728821&partnerID=8YFLogxK
U2 - 10.1086/315067
DO - 10.1086/315067
M3 - Article
C2 - 10515813
AN - SCOPUS:0032728821
VL - 180
SP - 1536
EP - 1541
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 5
ER -